Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules

[Image: see text] The frequency of brain disease has increased significantly in the past years. After diagnosis, therapeutic options are usually limited, which demands the development of innovative therapeutic strategies. The use of antibody–drug conjugates (ADCs) is promising but highly limited by...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavaco, Marco, Frutos, Silvia, Oliete, Paula, Valle, Javier, Andreu, David, Castanho, Miguel A. R. B., Vila-Perelló, Miquel, Neves, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437899/
https://www.ncbi.nlm.nih.gov/pubmed/36060671
http://dx.doi.org/10.1021/acsmedchemlett.1c00225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437899/
https://www.ncbi.nlm.nih.gov/pubmed/36060671
http://dx.doi.org/10.1021/acsmedchemlett.1c00225

Ejemplares similares